5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Broadwood Partners, L.P., a significant stakeholder in STAAR Surgical Co. (NASDAQ:STAA), recently purchased shares valued at approximately $481,849. The acquisitions occurred on March 4, 2025, with prices ranging from $16.30 to $17.74 per share, coming at a time when the stock has declined nearly 49% over the past year. According to InvestingPro data, STAAR maintains a strong liquidity position with a current ratio of 5.23. This move increases Broadwood Partners’ stake, with a total of 11,981,151 shares held post-transaction. The purchases were made directly by Broadwood Partners and indirectly through Broadwood Capital, Inc., under the leadership of Neal C. Bradsher, who is the President of Broadwood Capital. With a market capitalization of $885.1 million, STAAR currently shows a Fair overall financial health score according to InvestingPro, which offers comprehensive analysis and 8 additional key insights about the company’s prospects.
In other recent news, STAAR Surgical reported its fourth-quarter 2024 earnings, which missed both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.69, significantly below the expected -$0.03, while revenue came in at $48.95 million against a projected $77.2 million. This earnings miss has prompted several analyst actions, including Jefferies downgrading the stock and slashing its price target to $18 from $60, and Canaccord Genuity reducing its price target to $17 from $28 while maintaining a Hold rating. Additionally, Stifel cut its price target for STAAR Surgical to $20 from $38 but kept a Buy rating, citing concerns over the Chinese market’s impact on performance.
STAAR Surgical’s recent quarterly update highlighted challenges, particularly in the Chinese market, where the company faces inventory issues and uncertain sell-through performance with distributors. The company’s reliance on the Chinese market for recovery remains a concern, with the potential for a wide-ranging performance forecast in the second half of the year. Despite these challenges, STAAR Surgical maintains a strong cash position, ending the year with $230.5 million. The company is focusing on its EVO ICL (TASE:ICL) technology and anticipates launching EVO Plus in China, aiming for a recovery in the latter half of 2025.
Analyst firms have expressed varying levels of optimism about STAAR Surgical’s long-term prospects, with some firms seeing potential for recovery if market conditions stabilize. However, the near-term outlook remains cautious, with the company needing to address its challenges in the Chinese market and manage elevated inventory levels. The company’s strategic focus and strong balance sheet are seen as strengths as it navigates these difficulties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.